Publications en collaboration avec des chercheurs de Hospital General Universitario de Elche (15)

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2018

  1. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451

2017

  1. Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients

    Antiviral Therapy, Vol. 22, Núm. 1, pp. 21-29

  2. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study

    HIV Medicine, Vol. 18, Núm. 7, pp. 482-489

  3. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: A randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 5, pp. 1346-1351

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

2013

  1. Incidence and risk factors of AIDS-defining cancers in a cohort of HIV-positive adults: Importance of the definition of incident cases

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 5, pp. 304-312

  2. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: Role of antiretroviral therapy

    AIDS, Vol. 27, Núm. 2, pp. 181-189

2012

  1. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists

    AIDS Reviews, Vol. 14, Núm. 3, pp. 208-217

2011

  1. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients

    AIDS, Vol. 25, Núm. 6, pp. 761-766

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 12, pp. 5185-5196

2008

  1. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy

    Current HIV Research, Vol. 6, Núm. 2, pp. 100-107